SCHEMBL6402484

SCHEMBL6402484

N#CCCSc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
MAPK1 P28482 1/20 0.61
MAOA P21397 4/20 0.48
MAOB P27338 4/20 0.48
CYP2C19 P33261 4/20 0.42
CYP1A2 P05177 3/20 0.42
CYP2D6 P10635 3/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 1/20 0.42
HIF1A Q16665 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
FFAR1 O14842 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
CASP3 P42574 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10494843 0.87 ALDH1A1 (0.56) ALDH1A1MAPK1MAOAMAOBCYP2C19
SCHEMBL11617330 0.78 MAOA (0.49) ALDH1A1MAOAMAOBCYP2C19CYP1A2
SCHEMBL7835696 0.78 CYP19A1 (0.41) ALDH1A1MAPK1MAOAMAOB
SCHEMBL15856977 0.78 NPC1 (0.47) ALDH1A1MAPK1CYP2C19CYP1A2CYP3A4
SCHEMBL9451913 0.77 ALDH1A1 (0.61) ALDH1A1MAPK1MAOAMAOBCYP2C19
SCHEMBL776647 0.77 ALDH1A1 (1.00) ALDH1A1MAPK1MAOAMAOBCYP2C19
SCHEMBL4654471 0.77 MAOA (0.37) ALDH1A1MAPK1MAOAMAOBHTT
SCHEMBL11852467 0.77 LMNA (0.39) ALDH1A1MAPK1MAOAMAOBSMN1; SMN2
SCHEMBL8168991 0.77 MAOA (0.47) ALDH1A1MAPK1MAOAMAOBHTT
SCHEMBL1931888 0.76 ALDH1A1 (0.52) ALDH1A1MAPK1MAOAMAOBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190216726-A1 Particles, Compositions and Methods for Ophthalmic and/or Other Applications OXFORD FINANCE LLC 2019-07-18 US disclosed
WO-2018053321-A1 PARTICLES, COMPOSITIONS, AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS KALA PHARMACEUTICALS, INC. (US) 2018-03-22 WO disclosed
US-20050006246-A1 Nitrogen atom transfer YUDIN ANDREI K (CA) 2005-01-13 US disclosed
WO-2003010361-A2 NITROGEN ATOM TRANSFER YLEKTRA INC. (CA) 2003-02-06 WO disclosed
US-4536599-A HYDROLYZING THE NITRILE DERIVATIVE TO THE AMIDE USING AN ORGANIC QUATERNARY AMINE SALT CATALYST; EFFICIENCY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-08-20 US disclosed
EP-0040896-B1 SYNTHESIS OF AMIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1984-04-25 EP disclosed
US-4335787-A SURFACTANT SYSTEM COMPRISING A HYDROCARBON SULFONATE AND A NITRILE PHILLIPS PETROLEUM COMPANY (US) 1982-06-22 US disclosed
EP-0046451-A2 Diaryl-imidazole compounds, methods for their preparation, pharmaceutical drugs containing them and their use CIBA-GEIGY AG (CH) 1982-02-24 EP disclosed
EP-0040896-A2 Synthesis of amides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-12-02 EP disclosed
EP-0008532-A1 Synthesis of amines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-03-05 EP disclosed
US-3984336-A BETA-THIO-PROPIONITRILE, ANTIWEAR AGENTS MOBIL OIL CORPORATION (US) 1976-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190216726-A1 Particles, Compositions and Methods for Ophthalmic and/or Other Applications MUC1, RAB5IF, PDE6C ALDH1A1 2315/4885MAPK1 4809/4885MAOA 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.